Crinetics Announces 2021 Plans at J.P. Morgan Healthcare Conference


Scott Struthers, Ph.D., Founder & CEO of Crinetics, will present a company update on Wednesday, January 13th at 1:30 pm Pacific Time. A live audio webcast of Dr. Struthers’ presentation may be accessed on the Events section of the company’s website or directly on the J.P. Morgan virtual meeting platform.

Crinetics Pharmaceuticals to Participate in December Investor Conferences


Dr. Scott Struthers and Dr. Alan Krasner present at 32nd annual Piper Sandler Healthcare Conference December 1st-3rd, 2020 Webcast available until December 3rd.

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology


“Dr. Trainer is a global leader in the endocrine community who has treated patients, published extensively and educated physicians on the identification and treatment of endocrine disease, particularly in the area of neuroendocrinology,” said Alan S. Krasner, M.D., Chief Medical Officer of Crinetics.

Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for Treatment of Acromegaly


Crinetics hosts a virtual Key Opinion Leader (KOL) meeting on oral paltusotine for the treatment of acromegaly on Friday, November 20, 2020 at 11:00 am Eastern Time. Peter Trainer, MD and Monica Roberto Gadelha, MD, PhD discuss implications of Phase 2 ACROBAT studies with oral paltusotine.

Third Quarter 2020 Financial Results and Corporate Update


Positive topline results for Phase 2 trials of oral paltusotine (acromegaly), CRN04777 received Rare Pediatric Disease Designation (congenital hyperinsulinism)